3D-QSAR and molecular modeling of HIV-1 integrase inhibitors

Three-dimensional quantitative structure-activity relationship (3D QSAR) methods were applied on a series of inhibitors of HIV-1 integrase with respect to their inhibition of 3′-processing and 3′-end joining steps in vitro.The training set consisted of 27 compounds belonging to the class of thiazolothiazepines. The predictive ability of each model was evaluated using test set I consisting of four thiazolothiazepines and test set II comprised of seven compounds belonging to an entirely different structural class of coumarins. Maximum Common Substructure (MCS) based method was used to align the molecules and this was compared with other known methods of alignment. Two methods of 3D QSAR: comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were analyzed in terms of their predictive abilities. CoMSIA produced significantly better results for all correlations. The results indicate a strong correlation between the inhibitory activity of these compounds and the steric and electrostatic fields around them. CoMSIA models with considerable internal as well as external predictive ability were obtained. A poor correlation obtained with hydrophobic field indicates that the binding of thiazolothiazepines to HIV-1 integrase is mainly enthalpic in nature. Further the most active compound of the series was docked into the active site using the crystal structure of integrase. The binding site was formed by the amino acid residues 64-67, 116, 148, 151-152, 155-156, and 159. The comparison of coefficient contour maps with the steric and electrostatic properties of the receptor shows high level of compatibility.

[1]  V. Kulkarni,et al.  Three-dimensional quantitative structure-activity relationship of interleukin 1-beta converting enzyme inhibitors: A comparative molecular field analysis study. , 1999, Journal of medicinal chemistry.

[2]  S. Goff,et al.  Genetics of retroviral integration. , 1992, Annual review of genetics.

[3]  D. A. Dougherty,et al.  The Cationminus signpi Interaction. , 1997, Chemical reviews.

[4]  Vithal M. Kulkarni,et al.  Selectivity analysis of 5-(arylthio)-2,4-diaminoquinazolines as inhibitors of Candida albicans dihydrofolate reductase by molecular dynamics simulations , 2000, J. Comput. Aided Mol. Des..

[5]  M. Orozco,et al.  Molecular-mechanics modelling of drug-DNA structures; the effects of differing dielectric treatment on helix parameters and comparison with a fully solvated structural model. , 1990, Journal of biomolecular structure & dynamics.

[6]  Douglas D. Richman,et al.  HIV chemotherapy : AIDS , 2001 .

[7]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[8]  A. Engelman,et al.  Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication , 1995, Journal of virology.

[9]  M Le Bret,et al.  Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives. , 2000, Journal of medicinal chemistry.

[10]  Y. Pommier,et al.  Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors , 1997, Antimicrobial agents and chemotherapy.

[11]  Beat Ernst,et al.  Drug discovery today. , 2003, Current topics in medicinal chemistry.

[12]  Y. Pommier,et al.  Thiazolothiazepine inhibitors of HIV-1 integrase. , 1999, Journal of medicinal chemistry.

[13]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[14]  S. Ueda,et al.  Integration is essential for efficient gene expression of human immunodeficiency virus type 1 , 1993, Journal of virology.

[15]  M C Nicklaus,et al.  HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. , 1997, Journal of medicinal chemistry.

[16]  Gerhard Klebe,et al.  Comparative Molecular Similarity Indices Analysis: CoMSIA , 1998 .

[17]  T. Burke,et al.  Cell protein cross-linking by erbstatin and related compounds. , 1996, Biochemical Pharmacology.

[18]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[19]  V. Kulkarni,et al.  Comparative molecular field analysis of fungal squalene epoxidase inhibitors. , 1999, Journal of medicinal chemistry.

[20]  Erik De Clercq,et al.  Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. , 1995 .

[21]  M. Levitt,et al.  Refinement of protein conformations using a macromolecular energy minimization procedure. , 1969, Journal of molecular biology.

[22]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.

[23]  T R Burke,et al.  Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. , 1998, Journal of medicinal chemistry.

[24]  M C Nicklaus,et al.  Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. , 1997, Journal of medicinal chemistry.

[25]  Y. Pommier,et al.  Coumarin-based inhibitors of HIV integrase. , 1997, Journal of medicinal chemistry.

[26]  W. Schleif,et al.  Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells , 1992, Journal of virology.

[27]  J N Weinstein,et al.  Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study. , 1995, Journal of medicinal chemistry.

[28]  W. Haseltine,et al.  Integrase mutants of human immunodeficiency virus type 1 with a specific defect in integration , 1994, Journal of virology.

[29]  Tudor I. Oprea,et al.  Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules. , 1993, Journal of medicinal chemistry.

[30]  A Tropsha,et al.  Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. , 1995, Journal of medicinal chemistry.